PT - JOURNAL ARTICLE AU - D. Muilwijk AU - E. de Poel AU - P. van Mourik AU - S.W.F. Suen AU - A.M. Vonk AU - J.E. Brunsveld AU - E. Kruisselbrink AU - H. Oppelaar AU - M.C. Hagemeijer AU - G. Berkers AU - K.M. de Winter-de Groot AU - S. Heida-Michel AU - S.R. Jans AU - H. van Panhuis AU - M.M. van der Eerden AU - R. van der Meer AU - J. Roukema AU - E. Dompeling AU - E.J.M. Weersink AU - G.H. Koppelman AU - R. Vries AU - D.D. Zomer-van Ommen AU - M.J.C. Eijkemans AU - C.K. van der Ent AU - J.M. Beekman TI - Forskolin-induced swelling of intestinal organoids predicts long-term cystic fibrosis disease progression AID - 10.1101/2021.02.01.21250609 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.01.21250609 4099 - http://medrxiv.org/content/early/2021/02/03/2021.02.01.21250609.short 4100 - http://medrxiv.org/content/early/2021/02/03/2021.02.01.21250609.full AB - Patient-derived organoids hold great potential as predictive biomarker for disease expression or therapeutic response. Here, we used intestinal organoids to estimate individual cystic fibrosis transmembrane conductance regulator (CFTR) function of people with cystic fibrosis, a monogenic life-shortening disease associated with more than 2000 CFTR mutations and highly variable disease progression. In vitro CFTR function in CF intestinal organoids of 176 individuals with diverse CFTR mutations was quantified by forskolin induced swelling and was strongly associated with longitudinal changes of lung function and development of pancreatic insufficiency, CF-related liver disease and diabetes. This association was not observed when the commonly used biomarker of CFTR function sweat chloride concentration was used. The data strongly exemplifies the value of an organoid-based biomarker in a clinical disease setting and supports the prognostic value of forskolin induced swelling of intestinal organoids, especially for people with CF who have rare CFTR genotypes with unclear clinical consequences.Competing Interest StatementJ.M.B. and C.K.v.d.E. are inventors on patent(s) related to the FIS-assay and received financial royalties from 2017 onward. J.M.B report receiving research grant(s) and consultancy fees from various industries, including Vertex Pharmaceuticals, Proteostasis Therapeutics, Eloxx Pharmaceuticals, Teva Pharmaceutical Industries and Galapagos outside the submitted work. C.K.v.d.E report receiving research grant(s) grant(s) from Vertex Pharmaceuticals (money to institution) outside the submitted work. G.H.K. reports grants from Lung Foundation of the Netherlands, Vertex Pharmaceuticals, UBBO EMMIUS foundation, GSK, TEVA the Netherlands, TETRI Foundation, European Union (H2020) (all money to institution), outside the submitted work.Funding StatementThis work was supported by grants of the Dutch Cystic Fibrosis Foundation (NCFS) as part of the HIT-CF Program and by ZonMW.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Storage and use of intestinal organoids and the collection and linking of clinical data was approved by the Institutional Review Board (IRB) of the University Medical Center Utrecht (UMCU), The Netherlands and registered under number 14-008 (TC Biobank) and 16-668C (CCFR cohort).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and analyzed in the current study are available from the corresponding author on reasonable request.